Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression

Journal of Biological Engineering

Volumn 8, Issue 1, 2014, Pages

  Avci Adali, Meltem ^a   Behring, Andreas ^a   Keller, Timea ^a   Krajewski, Stefanie ^a   Schlensak, Christian ^a   Wendel, Hans P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

MRNA synthesis; Protein synthesis; Transfection

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; GLIAL FIBRILLARY ACIDIC PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; ENDOTHELIUM CELL; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC ENGINEERING AND GENE TECHNOLOGY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREACTIVITY; IN VITRO STUDY; MESSENGER RNA MODIFICATION; MESSENGER RNA SYNTHESIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA STABILITY; TRANSIENT EXPRESSION; CELLS BY BODY ANATOMY; GENETIC ENGINEERING; HEK293 CELL LINE; RNA SYNTHESIS; SOMATIC CELL;

EID: 84897571877     PISSN: None     EISSN: 17541611     Source Type: Journal    
DOI: 10.1186/1754-1611-8-8     Document Type: Article

References (15)

1. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, Griese M, Bittmann I, Handgretinger R, Hartl D, Rosenecker J, Rudolph C. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011, 29:154-157.
2. Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc 2013, 8:568-582.
3. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell stem cell 2010, 7:618-630.
4. Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010, 394:189-193.
5. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012, 30:1210-1216.
6. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
7. Kariko K, Weissman D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 2007, 10:523-532.
8. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, Kariko K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010, 38:5884-5892.
9. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008, 16:1833-1840.
10. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debré M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010, 363:355-364.
11. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, Asnafi V, MacIntyre E, Dal Cortivo L, Radford I, Brousse N, Sigaux F, Moshous D, Hauer J, Borkhardt A, Belohradsky BH, Wintergerst U, Velez MC, Leiva L, Sorensen R, Wulffraat N, Blanche S, Bushman FD, Fischer A, Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
12. Avci-Adali M, Kobba J, Neumann B, Lescan M, Perle N, Wilhelm N, Wiedmaier H, Schlensak C, Wendel HP. Application of a rotating bioreactor consisting of low-cost and ready-to-use medical disposables for in vitro evaluation of the endothelialization efficiency of small-caliber vascular prostheses. J Biomed Mater Res B Appl Biomater 2013, 101:1061-1068.
13. Bangel-Ruland N, Tomczak K, Fernandez EF, Leier G, Leciejewski B, Rudolph C, Rosenecker J, Weber WM. CFTR-mRNA delivery: a novel alternative for cystic fibrosis 'gene therapy'. J Gene Med 2013, 15:414-426.
14. Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AM, Corthals J, Ochsenreither S, Waelput W, Van Beneden K, Breckpot K, Van Tendeloo V, Thielemans K, Bonehill A. Design of an optimized Wilms' Tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity In Vitro and In Vivo. Mol Ther Nucleic Acids 2013, 2:e134.
15. Levy O, Zhao W, Mortensen LJ, Leblanc S, Tsang K, Fu M, Phillips JA, Sagar V, Anandakumaran P, Ngai J, Cui CH, Eimon P, Angel M, Lin CP, Yanik MF, Karp JM. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013, 122:e23-e32.